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Background: Specialized Early Intervention services (SEI) for first episode psychosis are shown to be effective for
the treatment of positive and negative symptoms, medication adherence, rates of relapse, substance abuse
disorders, functional outcome and quality of life at two-year treatment follow up. However, it is also reported that
these benefits are not maintained when SEI is not sustained. The objective of this trial is to test the efficacy of a
3-year extension of a SEI service (following 2 years of SEI prior to randomization) for the maintenance and
consolidation of therapeutic gains as compared to regular care in the community.
Methods: Following an initial 2 years of SEI, patients are randomized to receive either 3-years of continued SEI or
regular care. SEI provided at three sites within the McGill network of SEI services, using a model of treatment
comprised of: modified assertive case management; psycho education for families; multiple family intervention;
cognitive behavioural therapy; and substance abuse treatment and monitoring. Blinded research assistants conduct
ongoing evaluation of the outcome variables every three months. The primary outcome measure is remission status
measured both as the proportion of patients in complete remission and the mean length of remission achieved
following randomization during the additional three years of follow up. Based on preliminary data, it is determined
that a total of 212 patients are needed to achieve adequate statistical power. Intent to treat with the last observation
carried forward will be the primary method of statistical analysis.
Discussion: The “critical period” hypothesis posits that there is a five year window during which the effects of the
nascent psychotic illness can be countered and the impact of the disorder on symptomatic and functional outcomes
can be offset through active and sustained treatment. Providing SEI throughout this critical period may solidify the
benefits of treatment such that gains may be more sustainable over time as compared to intervention delivered for a
shorter period. Findings from this study will have implications for service provision in first episode psychosis.
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Psychotic disorders including schizophrenia spectrum
and affective psychosis are considered among the most
severe mental disorders [1], resulting in personal and
family suffering [2,3] and associated with poor long term
outcomes, particularly if not adequately treated [4-6].
The first episode of psychosis (FEP) typically occurs be-
tween adolescence and early adulthood [7] and interferes
with educational and employment attainment as well as
social transitions [8]. The life time prevalence of all
psychotic disorders, that include the presence of at least
one positive symptom, is up to 3.4% in the general
population [9]. In Canada alone, the overall economic
cost to society that includes loss of productivity as a re-
sult of psychosis is estimated at over six billion dollars
per year [10].
While most patients will respond positively to initial
treatment [11], the long-term prognosis is varied [12].
Only up to one quarter of all psychosis patients are
likely to achieve complete remission, depending on the
criteria and length of follow up applied [12,13]. Given
such likely negative outcomes, emphasis has been placed
on the earliest phase of psychosis, considered a “critical
period” of five years [14] when patients’ psychosocial
health may otherwise be most likely to decline [15] un-
less long term health trajectories are re-established [16].
Specialized Early Intervention (SEI) programs were first
initiated in the 1990s as a response to mounting evi-
dence of the importance of prevention, early detection
and appropriately targeted and timely treatment during
this critical period [17].
In comparison to regular care where the majority of
patients (80%) fail to sustain remission within the first
five years [18,19], FEP patients treated in an SEI model,
show higher rates of remission, lower rates of residual
positive and negative symptoms, lowered rates of re-
lapse, less substance abuse and better overall functioning
at one and at two years [11,20-24]. Indeed, the benefits
of SEI service as compared to treatment as usual over
the short term have been verified by three randomized
controlled trials [25-28] as well as uncontrolled studies
(for a meta-analytic review see Harvey et al., 2007 [29]).
Despite such encouraging outcomes, a five year uncon-
trolled study of FEP patients treated for 12 months in an
SEI service and then transferred into regular care
showed a loss of the beneficial effects achieved earlier in
treatment [30]. Critically, in a five year follow up study
(OPUS Trial) of a large sample of FEP patients, who had
received two years of SEI service before being trans-
ferred to regular care, the therapeutic gains achieved at
two years were not maintained over the following three
years [31].
This loss of advantage seen over the subsequent three
years during which SEI services were no longer availablemay have been prevented if the SEI service were contin-
ued throughout the critical five-year period in FEP. In a
recent study conducted in Canada, a reduced level of
SEI service was offered to all patients for three years be-
yond the standard first two years of SEI treatment [32].
Although there was no comparison group and the intensity
of SEI was lowered, patient outcome data after five years
(two years of SEI followed by three years of stepped down
SEI) when compared to the five-year outcome data of
OPUS patients who had only received two years of SEI
treatment were significantly better (rates of remission and
hospitalization) [32].
Based on the evidence reviewed above, the current
study is being conducted to address this question of
optimum treatment length using a randomized con-
trolled (RCT) design at the Prevention and Early Inter-
vention Program for Psychosis (PEPP-Montreal). In this
RCT we evaluate the effect of three years of extension of
full SEI services following two years of SEI, compared to
three years of regular care following the initial two years
of SEI service.
The primary hypothesis guiding this RCT is that in-
dividuals in the experimental group (extended SEI) will
show higher rates and longer periods of remission (both
positive and negative symptoms) than the control group
over the extension period of three years. The secondary
hypotheses are that: a) the difference in remission rates
are mediated by the level of medication adherence in
the two groups; b) as the experimental group is ex-
pected to have higher levels of working alliance with
their treatment providers than the control group, we
hypothesize that the difference in the level of medica-
tion adherence between the two groups and retention
in treatment is predicted by working alliance; c) that
the experimental group will have better clinical out-
comes (lower relapse rates and levels of symptoms),
functional outcomes (social/occupational functioning),
and quality of life than the control group. The eco-
nomic consequences of extending SEI past the standard
current 2 years is also being investigated, within the
RCT design, taking into consideration both direct and
indirect costs.Methods
Design
This trial is a randomized controlled trial comparing ex-
tended SEI for FEP (five years total) with treatment as
usual for FEP (two years of SEI followed by three years
of regular care). Prior to randomization, all patients re-
ceived their treatment from the McGill University net-
work of hospitals that offer SEI service according to a
common model of care within a defined catchment area
in the city of Montreal.
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Our aim is to use inclusion criteria that are as non
discriminatory as possible in order to ensure the eco-
logical validity of this trial and to reflect the kinds of di-
verse patients seen in FEP clinical settings. Although the
SEI services treat patients between 14 and 35 years old,
for the purpose of the study, patients aged 18–35, with a
DSM-IV diagnosis of a psychotic disorder (schizophrenia
spectrum psychoses and affective psychosis), who have
completed two years of SEI treatment and follow-up
within the McGill network of SEI services, an IQ
greater than 70, the ability to communicate in either
French or English, and the ability to provide informed
consent, are eligible for participation. Patients are re-
cruited regardless of their remission status at the end of
two years of SEI treatment, consistent with what may
be seen in regular clinical practice. Ethics approval for
this RCT was granted by McGill University’s Faculty of
Medicine Institutional Review Board (Assurance number:
FWA 00004545) and from the Douglas Hospital Research
Ethics Board.
Exclusion criteria
Patients who are not able to provide informed consent
(as determined by an inability to provide a brief sum-
mary of the treatment protocol following presentation of
the consent form); those with an inability to communi-
cate in either English or French; and those with an I.Q.
below 70 are ineligible for participation. Co-morbid sub-
stance abuse and dependence is not an exclusion
criteria.
Randomization
Randomization is stratified according to sex and sub-
stance abuse to ensure that these two factors, know to
influence outcome, are balanced between groups. Once
participants have signed informed consent to be ran-
domized, their initials and ID # are given to an on site
statistician who is not connected with the service.
Randomization to one of the two treatment conditions
is conducted using a computerized urn randomization
protocol [33]. Post-randomization, patients are asked
which condition they would have preferred to be ran-
domized to and if they are satisfied with the allocation
they were assigned. Results of the randomization are
communicated to the treatment team such that appro-
priate transfer decisions may be made, in the case that a
patient is randomized to regular care. This data will be
used as a covariate in case that treatment preference
biases outcomes (Figure 1).
Recruitment
Patients who have received ongoing modified case man-
agement for the entire two-year period are screened fortheir participation. Patients that meet the inclusion cri-
teria are approached for their participation between
months 21 and 24 of SEI from one of the three McGill
network SEI sites. The principal site of recruitment is
the Prevention and Early Intervention Program for
Psychosis (PEPP-Montreal), established in 2003 and the
largest of the three sites; FEP Program at the Jewish
General Hospital (established in 2007) and the PEPP at the
McGill University Health Centre (established in 2009).
Participants
Blinding
Neither the participants nor case managers and other
clinicians can be blinded to the assignment of the treat-
ment condition. However, trained research staff, not in-
volved in the patients’ care and blinded to the treatment
condition, conduct all assessments outside any of the pa-
tient treatment facilities. Baseline assessments are con-
ducted as soon as possible, within the first 3-6weeks of
randomization, in order to avoid revealing group assign-
ment. This is done to prevent any possibility of bias in
self-reports that could influence the comparability be-
tween groups. In cases where the blind is broken, add-
itional analyses, excluding the unblinded cases, will be
conducted to test for any effect of unblinding.
Interventions
The experimental intervention
Patients randomized to three years of extended SEI ser-
vice continue to have access to the entire package of
SEI services for an additional three years, following the
initial two years of SEI. The following services, offered
at the main PEPP site, constitute the experimental
intervention:
a. Modified assertive case management will continue to
be one of the core treatment services provided. The
case manager, with professional backgrounds
primarily in social work or nursing, who has been
involved in the patient’s care in the first two years,
continues to provide the same service. This includes
supporting the patient towards the attainment of
appropriate treatment goals with a moderate case
manager to patient ratio (20:1). Goals of treatment
typically emphasize adherence to antipsychotic
medication, reintegration into employment and/or
educational activities, improving patients’
understanding about their illness, reducing
dependence on hospital services, providing crisis
intervention, promoting independence, monitoring
early signs of relapse and reducing the risk of being
engulfed by the illness. A personalized profile of the
patients’ early warning signs [34,35] is created jointly
in collaboration with the patient and used as a tool
Figure 1 Diagram of study participants in PEPP trial of extended SEI.
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symptoms that might signal future relapse. Case
management is provided as per the patients’ needs,
using a guideline of a minimum of two contacts per
month.
b. Multiple Family Intervention is offered to the
patient’s family as booster sessions of structured
family education intervention and multiple family
group intervention [36] similar to what is offered
during the first two years.
b. Psychoeducation for families is offered once a year
and as booster sessions to the patient’s family.
Workshops are designed as three two-hour sessions
where families can ask questions and learn about
psychosis, treatment and support.
c. Cognitive behaviour therapy (CBT), known to be
highly effective for those with psychosis [37,38], is
offered in the case of a major depressive episode,
anxiety disorder or residual psychotic and/or
negative symptoms.
d Substance abuse education and monitoring for
problems associated with substance abuse is offered
to patients who, at initial presentation had aco-morbid diagnosis of substance abuse or developed
substance abuse during the first two years of
treatment. Therapists have received training to
provide a brief (one-two sessions of 40–60 minutes
each) intervention based on Motivational Interviewing
[39]. The administration of the Timeline Follow-Back
procedure followed by feedback [40] is used to
help patients track their own alcohol and drug
consumption. Patients are referred to appropriate
rehabilitation if needed.
The control intervention
Patients randomized to the control condition receive
treatment as usual in general medical or regular psychi-
atric services that are available for free to all Quebec pa-
tients. Primary regular care in Quebec is predominantly
offered through local health and community services
centres (CLSCs) that provide health and social services
to their catchment area. Care by a family physician in
the community is provided in a variety of settings, in-
cluding at CLSCs and private clinics, and is of variable
quality and intensity. Secondary (psychiatric) regular
care, including hospital in- and out-patient services,
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are part of regular care available to all patients random-
ized to the control condition.
Assessments
Evaluations and assessments are carried out at entry and
every three months thereafter for the entire follow up
period, or until withdrawal from the study, for both
treatment conditions (details of assessments are pro-
vided in Table 1). If a patient withdraws, they are asked
to provide one last assessment. When no contact has
been made for 3 consecutive assessment periods (for a
total of 9 months) and attempts made for contact
through phone calls, emails, and contact with care pro-
viders including family members, are not successful, the
patient is considered to be withdrawn. Trained evalua-
tors will conduct assessments largely through a semi
structured interview format.
Data on the Duration of Untreated Psychosis (DUP)
are available for all PEPP patients and is derived using
the Circumstances of Onset and Relapse Schedule
(CORS) [11], a structured interview instrument for use
with patients and families that includes some sectionsTable 1 Assessment instruments
Assessment Instrument
Psychopathology Scale for the Assessment
Scale for the Assessment
Positive and Negative Sy
Brief Psychiatric Rating S




Life Skills Profile [48]**
Medication and side effects Patient Compliance Inter
Medication Compliance:
Substance use Chemical Use/Abuse/De
Time Line Follow Back [4
Working alliance Working Alliance Invento
Randomization preference Self administered questio
Quality of life Life Satisfaction and Psyc
version [53]**
Duration of untreated psychosis Circumstances of Onset
Promorbid adjustment Premorbid Adjustment S





*Assessed at each evaluation (every 3 months).
**Assessed at every second evaluation (every 6 months).
***Assessed once at baseline.
****Assessed post study completion.from the Interview for the Retrospective Assessment of
Onset of Schizophrenia (IRAOS) [54]. DUP data for all
other patients is available through chart verification.
Outcomes
In light of more recent consensus criteria for remission
that emphasizes the amelioration of positive as well as
negative symptoms and a return to social and occupa-
tional functioning [55], a full range of complementary
measures of clinical and functional outcome is being ex-
amined both separately and in context with each other.
Primary outcome
The primary outcome is complete remission measured
as both the proportion of patients in remission, as well
as the mean length of remission achieved following
randomization during the additional three years of
follow up. Complete remission is defined according to
consensus criteria as a rating of mild or less on the fol-
lowing positive and negative symptom scale items (Posi-
tive domain: hallucinations, delusions, bizarre behaviour,
positive formal thought disorder; Negative domain:
affective flattening or blunting; alogia; avolition-apathy;of Positive Symptoms (SAPS) [41]*
Negative Symptoms (SANS) [42]*
ndrome Scale (PANSS) [43]*
cale (BPRS) [44]*
nctioning Scale (GAF) [45]*
Functioning Scale (SOFAS) [46]**
estionnaire (adapted from the Client Socio-Demographic and Service
view [49]*





hological Well-being domains of the Wisconsin Quality of Life-Client
and Relapse Schedule (CORS) [11]***
cale (PAS) [52]***
nnaire with list of services received
ladie du Quebec (Quebec medical insurance; RAMQ)****
ations)****
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Complete remission is chosen as the primary outcome
measure as per findings that remission across both
symptom domains is a better predictor of functional out-
come than remission of positive symptoms alone [56,57].
Remission is measured at each assessment covering the
three months prior using the Scale for Assessment of
Positive Symptoms [41] and the Scale for the Assess-
ment of Negative Symptoms [42]. The SANS domain of
Attention is not included in SANS ratings as these items
have not been shown to correlate to the domain of nega-
tive symptoms [58].
Secondary outcomes
a) Clinical outcome: (i) Relapse (defined as the
reemergence of positive symptoms as measured by a
global item on the SAPS of at least 3 in severity that
leads to an increase or change in antipsychotic
medication or to hospital admission) [59]; (ii) Level
of positive and negative symptoms (SAPS [41] and
SANS [42] ratings); (iii) Global Assessment of
Functioning (GAF) [45]; (iv) Discontinuation of
treatment as determined through a lack of service
use.
b) Functional outcome (assessed on two functional
dimensions): (i) role functioning (paid employment,
school attendance, and/or meaningful housework)
and through; (ii) social functioning (such as
independence in community living) assessed using
the Life Skills Profile [48] as well as the Social and
Occupational Functioning Scale (SOFAS) [46] as a
global measure of functioning.
c) Quality of Life (QOL): Subjective reporting of QOL
is assessed at study entry and subsequently at every
six months using the Life Satisfaction and
Psychological Well-being domains of the Wisconsin
Quality of Life-Client version [53].
Mediating variables
a) Adherence to medication is assessed through patient
and family reports (when available), and pill counts
are conducted by the evaluator. Ratings are made on
a five point scale ranging from 0 = not taking
medication when prescribed, to 5 = taking
medication all of the time as prescribed.
b) Working alliance with respective service providers is
measured with the Working Alliance Inventory-
patient version, a self-report instrument [52]
c) Premorbid adjustment has been shown to be of
importance to clinical outcome [11,18] and is
assessed with the Premorbid Adjustment Scale [60]
at time of entry into the trial in case that such datawas not already collected as part of the initial
protocol of entry into PEPP-Montreal.Economic analysis
Administrative databases are utilized to assess costs as-
sociated medical services. The Regie de l’Assurance-
maladie du Quebec (RAMQ) provides free public health
and prescription drug insurance plans to all eligible
Quebec residents. RAMQ databases are consulted for
physician services (all patients) and filled prescriptions
for patients with public coverage (approximately 90% of
patients), and Med-Echo, for hospitalizations. Question-
naires, administered at baseline and every three months
following are utilized to record data on any other health
care usage as well as for patient and family time involve-
ment in receiving such treatment. We request consent
to access this database as part of the initial informed
consent. This information is used to track overall soci-
etal and economic costs associated with patient treat-
ment in both the experimental and control groups.Training and inter-rater reliability
All service care providers and assessors acquire intensive
onsite training in their field and are supervised by the
principal investigator (A.M), co-PI (R.J) and the PEPP
research coordinator (S.A). Assessors have achieved high
inter rater reliability (range 0.75-0.92) and are able to
consult with the project coordinator should any ques-
tions arise.Power and sample size
Power Analysis for sample size calculation is based on
the proportion of SEI patients that were in remission of
positive symptoms in the last two years of the OPUS
trial (41.8%) [31] and the proportion of SEI patients that
were in remission in the last two years of the uncon-
trolled outcome study conducted at PEPP–London
(69%) [32]. Assuming conservatively a 5% greater pro-
portion of patients in remission for the control condition
than in the OPUS trial and a 5% smaller proportion for
the experimental condition than in the PEPP-London
study, it is estimated that a sample size of 82 in each
group (total of 164) will achieve 80% power to detect a
difference between groups. Given the rates of attrition
between the beginning of the third and the end of the
fifth years from the OPUS extension trial that were 18%
[31] and from the PEPP-London study that were 12%
[32], we expect rates of 25% and <20% over the same
period from the control and experimental conditions re-
spectively. Recruitment of participants are adjusted from
n =164 to n = 212 to account for possible dropouts.
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For the purpose of this trial, dropouts are considered
those with three assessments in a row that are missing.
To reduce attrition, our study coordinator contacts
anyone who has missed two assessments in a row,
prior to their next scheduled evaluation. When a drop-
out has occurred, an effort is made to ascertain the
reason for the dropout and to conduct a final assess-
ment for the primary outcome (remission status). If a
patient drops out of treatment but continues to con-
sent to using their data, medical files for their case are
located to obtain information on many of the outcome
measures.Statistical analyses
Data analysis is based on the intent to treat principle.
All patient evaluations will be included in the analysis.
To assess homogeneity at baseline, relevant demographic
data will be presented.
For the primary outcome measures, the proportion
of patients in remission in the experimental and con-
trol groups will be compared using a Pearson chi-
square statistic and the mean length of remission with
a t-test or Wilcoxon test for independent samples,
based on the distribution of the independent variable.
Logistic regression analyses and multiple regression
analyses will also be performed with all covariates and
mediators.
For the secondary outcome measures including relapse
(relapse vs. no relapse), dichotomous outcomes will be
analyzed using logistic regression with covariates. Time
to Event (relapse) will be measured using a Kaplan-
Meier methods and Cox regression to analyze intervals
of time from randomization to relapse. Continuous out-
comes that include clinical outcomes will be assessed
using regression models with covariates and finally lon-
gitudinal data with repeated measurements will be ana-
lyzed using repeated measures of analysis of variance.
Missing data will be assessed to determine if they are
random or informative. Should missing data be non ig-
norable, then selection models and pattern-mixture
models will be used to evaluate the robustness of the
primary analyses.Ethical considerations
All patients randomized to either continued SEI or to
regular care following two years of SEI are offered treat-
ment according to best practice. Participants are in-
formed about the trial and about the voluntary nature of
their participation with both written and verbal commu-
nications. Participants are only randomized following
the provision of informed consent.Trial status
Currently all participants (n = 220) have been recruited
and are randomized with n = 109 in the experimental
group and n = 111 in the control condition (extended
SEI vs. regular care). Participants are being followed with
the last patient assessments scheduled for 2015.
Discussion
This study is based on previous data that suggests that
the benefits of SEI services in FEP at two years are lost
at five-year follow up if patients return to regular care
[31]. Given the severity of psychosis and the individual
and societal costs associated with this disorder, there is a
need for research that can better guide best practices.
That FEP patients are young and potentially still malle-
able to treatment, suggests the importance of positively
influencing long-term trajectories of outcome. To our
knowledge, this is the first RCT trial of its kind in North
America, and one of only two such trials anywhere
(OPUS-II) [61], being carried out currently to assess the
impact of extended SEI for a total of five years in FEP.
Several strengths of this study include the number of
participants recruited as well as the computerized
randomization procedure that ensures chance allocation
to group. That we have included FEP patients with co-
morbid disorders, including comorbid substance use,
and that patients in our control condition are likely to
be filtered through a wide range of 1st, 2nd, and 3rd line
services available, gives critical construct validity to our
study. Given that the majority of service is provided out
of a single site (PEPP-Montreal) with two satellite clinics
that are closely aligned and that follow the same treat-
ment system, homogeneity of service infrastructure and
fidelity to the same SEI model of care is ensured. As
well, we are measuring a host of critical variables that
may give meaning to the context of remission. Variables
including social and occupational functioning and nega-
tive symptoms at baseline have been shown to impact
long-term trajectories in FEP [12,13]. Measures of quality
of life bring into focus the personal perspectives of this
disorder while concurrent measures of all associated
economic costs will highlight societal burden. This trial
is registered http://www.isrctn.com/ (ISRCTN11889976),
which helps to ensure complete reporting.
A limitation of any service based trial is that we are
unable to blind participants or service providers to treat-
ment allocation. While participants may not receive
their preferred allocation in either condition, this possi-
bility is discussed beforehand. That assessors are inde-
pendent of treatment providers and conduct their
evaluations blind to the treatment allocation outside of
the patients’ treatment location will reduce chances of
unblinding the treatment assignment and ensure the in-
tegrity of symptom and functional assessments.
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Despite the growth of SEI services across the world, the
optimum length of SEI services in FEPP has not been
ascertained and remains an important issue for treat-
ment providers, service users, and policy makers. Results
of this RCT are likely to have major impact on treatment
of FEP and the recommendation of an optimal duration
of SEI services. Should an extension of SEI serve to im-
prove outcomes for patients with a FEP, this will be a
major benefit to individuals, families and to society.
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